AMDC-USR
Phase 3Biologic
AMDC-USR is one of 4 biologic programs targeting Stress urinary incontinence. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Stress Urinary Incontinence
#DrugCompanyPhaseTrials
1AMDC-USR
CCook MyoSite
Phase 3
Activella
Eli LillyPreclinical
Andriol
AAuxilium
Preclinical
Propiverine Hydrochloride
LLee's Pharmaceutical Limited
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AMDC-USR. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- CCook MyoSite